書誌事項
- タイトル別名
-
- Antitumor activity of RES-avoiding liposomal 5'-Dipalmitoylphosphatidyl 2'-C-Cyano-2'-deoxy-1-.BETA.-D-arabino-pentofuranosylcytosine(DPP-CNDAC).
この論文をさがす
抄録
2'-C-Cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC) has been developed as a novel antitumor nucleoside. 5'-Dipalmitoylphosphatidyl derivative of CNDAC (DPP-CNDAC) also has a significant antitumor activity and is readily incorporated in liposomes. Therefore, to reduce the side effects and to enhance the antitumor activity, we incorporated DPP-CNDAC into reticuloendothelial systems (RES)-avoiding, long circulating, liposomes modified with palmityl-D-glucuronide (PGlcUA), which tend to accumulate passively in tumor tissues. When liposomal DPP-CNDAC modified with PGlcUA was injected intravenously into Meth A sarcoma-bearing mice, it showed higher antitumor activities and increased more the life span of mice, compared to those obtained by injection of DPP-CNDAC only or by liposomal DPP-CNDAC without PGlcUA. Thus, the incorporation of DPP-CNDAC into liposoma membrane modified with PGlcUA may be useful as a formulation of this anticancer agent.
収録刊行物
-
- Drug Delivery System
-
Drug Delivery System 13 (5), 341-346, 1998
日本DDS学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204641074944
-
- NII論文ID
- 10007338152
-
- NII書誌ID
- AN10084591
-
- ISSN
- 18812732
- 09135006
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可